Skye Bioscience, Inc. (SKYE)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
0.79 USD
+0.04
(5.187%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.79 +0.00 (0.076%) ⇧ (April 17, 2026, 7:29 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.184919 |
| MSTL | 0.349891 |
| AutoETS | 0.372103 |
| AutoARIMA | 0.372107 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.079 |
| Excess Kurtosis | 0.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.367 |
| Market Cap | 27,711,600 |
| Forward P/E | -0.83 |
| Beta | 2.87 |
| Previous Name | Emerald Bioscience Inc. |
| Website | https://skyebioscience.com |
As of April 18, 2026, 10:37 p.m. EDT: Options activity shows a distinct contrarian sentiment. While there is trivial Calls volume, significant Put inventory is concentrated at the June 18th expiration, specifically at-in-the-money (Strike 2.50) and further out-of-the-money (Strike 5.00). This heavy positioning of puts versus the absence of calls suggests speculators are heavily hedging for downside risk or positioning for a continued decline to the 0.57 support level, despite the current price drift higher from recent lows. Implied volatility remains extremely low on both sides, indicating sparse liquidity in protective premiums beyond the current spot.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.49745226 |
| Address1 | 11,250 El Camino Real |
| Address2 | Suite 100 |
| All Time High | 1,937.5 |
| All Time Low | 0.566 |
| Ask | 0.8219 |
| Ask Size | 1 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 179,180 |
| Average Daily Volume3 Month | 543,151 |
| Average Volume | 543,151 |
| Average Volume10Days | 179,180 |
| Beta | 2.869 |
| Bid | 0.7557 |
| Bid Size | 1 |
| Book Value | 0.6 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7889 |
| Current Ratio | 3.302 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.7999 |
| Day Low | 0.751 |
| Debt To Equity | 1.367 |
| Display Name | Skye Bioscience |
| Earnings Call Timestamp End | 1,773,174,600 |
| Earnings Call Timestamp Start | 1,773,174,600 |
| Earnings Timestamp | 1,773,172,800 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -57,440,212 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.015 |
| Enterprise Value | 868,931 |
| Eps Current Year | -0.97667 |
| Eps Forward | -0.95 |
| Eps Trailing Twelve Months | -1.41 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.7184 |
| Fifty Day Average Change | 0.070500016 |
| Fifty Day Average Change Percent | 0.09813476 |
| Fifty Two Week Change Percent | -49.745224 |
| Fifty Two Week High | 5.75 |
| Fifty Two Week High Change | -4.9611 |
| Fifty Two Week High Change Percent | -0.8628 |
| Fifty Two Week Low | 0.566 |
| Fifty Two Week Low Change | 0.22290003 |
| Fifty Two Week Low Change Percent | 0.39381632 |
| Fifty Two Week Range | 0.566 - 5.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,420,554,600,000 |
| Float Shares | 21,203,526 |
| Forward Eps | -0.95 |
| Forward P E | -0.8304211 |
| Free Cashflow | -22,953,560 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 12 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.011720001 |
| Held Percent Institutions | 0.46007 |
| Implied Shares Outstanding | 35,126,884 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-04-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,694,131,200 |
| Last Split Factor | 1:250 |
| Long Business Summary | Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California. |
| Long Name | Skye Bioscience, Inc. |
| Market | us_market |
| Market Cap | 27,711,600 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_266974060 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -55,924,816 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 27,792,390 |
| Number Of Analyst Opinions | 8 |
| Open | 0.751 |
| Operating Cashflow | -43,062,528 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 410 0266 |
| Post Market Change | 0.00059998035 |
| Post Market Change Percent | 0.07605278 |
| Post Market Price | 0.7895 |
| Post Market Time | 1,776,468,574 |
| Prev Name | Emerald Bioscience Inc. |
| Previous Close | 0.75 |
| Price Eps Current Year | -0.8077447 |
| Price Hint | 4 |
| Price To Book | 1.3148333 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.138 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.75 |
| Region | US |
| Regular Market Change | 0.0389 |
| Regular Market Change Percent | 5.18667 |
| Regular Market Day High | 0.7999 |
| Regular Market Day Low | 0.751 |
| Regular Market Day Range | 0.751 - 0.7999 |
| Regular Market Open | 0.751 |
| Regular Market Previous Close | 0.75 |
| Regular Market Price | 0.7889 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 234,896 |
| Return On Assets | -0.71929 |
| Return On Equity | -1.26848 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 35,126,884 |
| Shares Percent Shares Out | 0.0479 |
| Shares Short | 1,598,033 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 967,400 |
| Short Name | Skye Bioscience, Inc. |
| Short Percent Of Float | 0.0694 |
| Short Ratio | 1.55 |
| Source Interval | 15 |
| State | CA |
| Symbol | SKYE |
| Target High Price | 20.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 8.25 |
| Target Median Price | 7.5 |
| Total Cash | 25,737,220 |
| Total Cash Per Share | 0.771 |
| Total Debt | 273,646 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.949585 |
| Two Hundred Day Average Change | -1.160685 |
| Two Hundred Day Average Change Percent | -0.5953498 |
| Type Disp | Equity |
| Volume | 234,896 |
| Website | https://skyebioscience.com |
| Zip | 92,130 |